Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

The considerable public health burden due to cytomegalovirus (CMV) supports current interest in vaccine development. Clinical studies intended to support regulatory action should be designed to demonstrate substantial evidence of effectiveness. However, design and conduct of clinical endpoint studies may be hampered by low incidence of disease, especially for congenital CMV. Discussion and experience from other vaccines directed against congenital disease (including rubella and Zika) may be instructive. This article summarizes current scientific and US regulatory considerations related to design of studies of vaccines intended to prevent congenital CMV and complications of CMV in transplantation, as discussed at the 2018 workshop entitled "Cytomegalovirus Infection: Advancing Strategies for Prevention and Treatment." Published by Oxford University Press for the Infectious Diseases Society of America 2020.


Philip R Krause, Jeff Roberts. Scientific and Regulatory Considerations for Efficacy Studies of Cytomegalovirus Vaccines. The Journal of infectious diseases. 2020 Mar 05;221(Suppl 1):S103-S108

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 32134485

View Full Text